Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

0.8854
-0.0618-6.52%
Post-market: 0.91000.0246+2.78%18:34 EDT
Volume:6.87M
Turnover:6.15M
Market Cap:299.72M
PE:-3.47
High:0.9454
Open:0.9454
Low:0.8700
Close:0.9472
52wk High:2.73
52wk Low:0.8700
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.88
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-18.10
PE(LYR):-3.92

Loading ...

Ocugen Inc. Stock Falls 6.5%, Underperforms Market

Dow Jones
·
2 hours ago

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Oct 10

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Oct 09

Ocugen Inc. Stock Falls 3.8%, Underperforms Market

Dow Jones
·
Oct 08

Ocugen Names Jolanda Crombach General Manager of European Affiliate

Reuters
·
Oct 06

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

THOMSON REUTERS
·
Oct 06

Ocugen Reconvenes Special Shareholder Meeting, Adjourns Vote on Authorized Share Increase Proposal

Reuters
·
Oct 06

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Oct 06

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
Oct 03

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Oct 02

Ocugen Inc. Stock Sheds 5.5%, Underperforms Market

Dow Jones
·
Oct 01

Analyst Maintains Buy Rating on Ocugen as OCU400’s Early Revenue Pathway and Phase 3 Upside Support Unchanged $11 Price Target

TIPRANKS
·
Sep 30

Ocugen to Present 12-Month Phase 2 ArMaDa Trial Results for Ocu410 Gene Therapy in Geographic Atrophy at AAO 2026

Reuters
·
Sep 30

Ocugen to Participate in Upcoming Scientific Conferences

GlobeNewswire
·
Sep 30

Ocugen Inc. Stock Rallies 5.8%, Outperforms Market

Dow Jones
·
Sep 30

Ocugen CEO Musunuri Moderates H.C. Wainwright Biotech on Tap Panel

Reuters
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
Sep 26

Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas

Dow Jones
·
Sep 25

Ocugen Wins Provisional Approval for Ocu400 in Bahamas Under LARTA Pathway

Reuters
·
Sep 25